相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases
Li Yang et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2022)
Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre
Joel A. Vanderniet et al.
BONE (2022)
Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications
Cindy Y. Jiang et al.
ONCOLOGIST (2022)
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
Aneta Maria Borkowska et al.
CANCERS (2022)
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
CLINICAL TRIALS (2021)
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
Hengyuan Li et al.
FRONTIERS IN ONCOLOGY (2020)
In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid
Isao Shibuya et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2019)
Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone
Feiyan Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
Jacob Engellau et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)
Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway
Zong-Yuan Jiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
Czar Louie Gaston et al.
CLINICAL SARCOMA RESEARCH (2016)
The growing problem of benign connective tissue tumours
David M. Thomas
LANCET ONCOLOGY (2015)
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
David Henry et al.
SUPPORTIVE CARE IN CANCER (2014)
Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation
Dominik Peus et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2013)
Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of three pivotal, randomised, phase 3 trials
Kazuhiro Araki et al.
EUROPEAN JOURNAL OF CANCER (2013)
Denosumab treatment of giant cell tumour of bone
Maurice Balke
LANCET ONCOLOGY (2013)
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2013)
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
Kaitlin Koo et al.
SUPPORTIVE CARE IN CANCER (2013)
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Daniel G. Branstetter et al.
CLINICAL CANCER RESEARCH (2012)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Jipan Xie et al.
JOURNAL OF MANAGED CARE PHARMACY (2011)
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone
Maurice Balke et al.
BMC CANCER (2010)
Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
Maurice Balke et al.
LANCET ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study
Lung Fung Tse et al.
BONE (2008)